Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Advair 250 Clear all

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol, Fluticasone Propionate/Salmeterol Combination Product; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 85
States / cities: Birmingham, Alabama • Jasper, Alabama • Glendale, Arizona + 78 more

Conditions: Asthma
Interventions: ADVAIR 100/50mcg, ADVAIR 250/50mcg, ADVAIR 500/50mcg, FLOVENT 100mcg, FLOVENT 250mcg, FLOVENT 500mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 11,751 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 350
States / cities: Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 273 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Umeclidinium/vilanterol, Fluticasone propionate/salmeterol, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 707 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 9
States / cities: Jasper, Alabama • Phoenix, Arizona • San Diego, California + 6 more

Conditions: Asthma, COPD
Interventions: MGR001, Advair® Diskus®, Seretide™ Accuhaler™; Drug
Lead sponsor: Mylan Pharma UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Propionate/Salmeterol DISKUS 250/50mcg, Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Jasper, Alabama • Mobile, Alabama • Lafayette, Louisiana + 13 more

Conditions: Asthma
Interventions: Flovent Diskus, Home Environmental Intervention, Advair Diskus; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 5 Years to 17 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Obstructive Pulmonary Disease, Depression
Interventions: Advair diskus; Drug
Lead sponsor: Valley Medical Research; Other
Eligibility: 18 Years to 94 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Brooksville, Florida • Centerville, Ohio

Conditions: Chronic Obstructive Pulmonary Disease, Sleep Disorders
Interventions: salmeterol-fluticasone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Salmeterol, Fluticasone Propionate/Salmeterol Combination Product; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 7 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Fluticasone Propionate/Salmeterol Combination Product, Salmeterol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 95
States / cities: Jasper, Alabama • Mobile, Alabama • Glendale, Arizona + 88 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Fluticasone Propionate/Formoterol Fumarate, Fluticasone Propionate, Formoterol Fumarate, Fluticasone Propionate/Salmeterol Xinafoate, Placebo; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 457 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 49
States / cities: Birmingham, Alabama • Jasper, Alabama • Phoenix, Arizona + 44 more

Conditions: Asthma, Candidiasis, Oral, Voice Disorders
Interventions: fluticasone/salmeterol DISKUS 250/50; Drug
Lead sponsor: Allergy & Asthma Medical Group & Research Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: San Diego, California

Conditions: COPD
Interventions: fluticasone 100mcg/ salmeterol 50mcg, fluticasone 250/salmeterol 50, Salmeterol, salmeterol and fluticasone propionate; Drug
Lead sponsor: Arthur F Gelb MD; Individual
Eligibility: 20 Years to 85 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: Asthma
Interventions: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 621 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 58
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • Fountain Valley, California + 48 more

Conditions: Asthma
Interventions: fluticasone/salmeterol in all asthmatics, budesonide/formoterol or fluticasone/salmeterol in all asthmatics; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 10 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Asthma
Interventions: fluticasone propionate + montelukast, fluticasone propionate, fluticasone propionate + salmeterol; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 5
States / cities: Tucson, Arizona • San Diego, California • Denver, Colorado + 2 more

Conditions: Asthma
Interventions: budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 10 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Lakewood, California

Conditions: COPD
Interventions: Placebo, Fluticasone /salmeterol; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS 250/50 mg BID, SEREVENT 50 mcg BID; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 74
States / cities: Birmingham, Alabama • Florence, Alabama • Mobile, Alabama + 66 more

Conditions: COPD
Interventions: Advair 250, Placebo- matched, Placebo, Advair 250 - matched; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 45 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Asthma
Interventions: ADVAIR 100/50mcg, ADVAIR 250/50mcg, FLOVENT 100mcg, FLOVENT 250mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 6,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 267
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 208 more

Conditions: Asthma
Interventions: zileuton; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 21 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Asthma
Interventions: Xolair injections; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies.

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

A Study to Compare the Efficacy and Safety of Umeclidinium/Vilanterol and Fluticasone Propionate/Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Bioequivalence Study to Assess Systemic Exposure of FP and SAL FDC From Different DPIs

Advair HFA For Chronic Obstructive Pulmonary Disease(COPD)

Environmental Control as Add-on Therapy in Childhood Asthma

The Effect on Depressive Symptoms in ECF Residents With COPD

The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD

ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies.

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease

Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

Zileuton and Exhaled Nitric Oxide in Asthmatics

Non-invasive Measures of Effects of Xolair in Asthma